ArticleFrontiers in public health2025
Bridging the gap: tackling general and HPV vaccine hesitancy in rural and low-vaccination areas to improve HPV vaccine uptake.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite strong efforts, HPV vaccine uptake remains low, especially in rural areas. This study examined general and HPV vaccine hesitancy among parents of children aged 9-17 in rural, low-vaccination areas, its link to HPV vaccination rates, and key factors influencing hesitancy. Methods: We surveyed parents from three counties in Virginia and collected information about their beliefs and opinions regarding adolescent vaccines, particularly the HPV vaccine, and their child's HPV vaccination status. General and HPV vaccine hesitancy were assessed using validated scales. Bayesian index logistic regression models were used to examine the relationship between each index and the child's HPV vaccination status, and also to identify the most important factor within each index. Results: The final analytical sample included 249 complete responses. The average reported child age was 12.4 years; 62.0% of parents reported that their child had received the HPV vaccine. In the adjusted general vaccine hesitancy model, hesitancy was significantly associated with a lower likelihood of a child's HPV vaccination (OR = 0.43, 95% CI: 0.26, 0.73), with perceived vaccine safety (weight = 0.363) the most influential factor estimated within the index. Similarly, in the adjusted HPV vaccine hesitancy model, hesitancy was significantly associated with a child's HPV vaccination (OR = 0.39, 95% CI: 0.20-0.72), with provider recommendation (weight = 0.198) the dominant estimated factor. Conclusion: Vaccine hesitancy remains a substantial challenge for HPV vaccination. Engaging providers to give strong vaccine recommendations and sharing information about vaccine safety, among other strategies, could help improve HPV vaccine uptake in rural and low-vaccination areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.